Patient preference disability questionnaire in systemic sclerosis: A cross-sectional survey

Arthritis Care and Research

Volumn 59, Issue 7, 2008, Pages 968-973

  Mouthon, Luc ^a,b   Rannou, François ^a,c   Bérezné, Alice ^a,b   Pagnoux, Christian ^a,b   Guilpain, Philippe ^a,b   Goldwasser, François ^b   Revel, Michel ^a,c   Guillevin, Loïc ^a,b   Fermanian, Jacques ^a,d   Poiraudeau, Serge ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Cochin Hospital ^*  (France)

^c University Paris Descartes   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COCHIN HAND FUNCTION SCALE; CONSTRUCT VALIDITY; DISABILITY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MCMASTER TORONTO ARTHRITIS PATIENT PREFERENCE DISABILITY QUESTIONNAIRE; MOUTH HANDICAP IN SYSTEMIC SCLEROSIS SCALE; QUESTIONNAIRE; RATING SCALE; SPORT; SYSTEMIC SCLEROSIS; WALKING;

ACTIVITIES OF DAILY LIVING; AGED; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT PARTICIPATION; QUALITY OF LIFE; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 47249163373     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23819     Document Type: Article

References (29)

1. Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003;2:152-7.
2. Servettaz A, Agard C, Tamby MC, Guilpain P, Guillevin L, Mouthon L. Systemic sclerosis: pathophysiology of a multifaceted disease. Presse Med 2006;35:1903-15. In French.
3. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
4. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
5. Casale R, Buonocore M, Matucci-Cerinic M. Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Arch Phys Med Rehabil 1997;78:767-73.
6. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-3.
7. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-6.
8. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4:27-31.
9. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
10. Brower LM, Poole JL. Reliability and validity of the Duruöz Hand Index in persons with systemic sclerosis (scleroderma). Arthritis Rheum 2004;51:805-9.
11. Rannou F, Poiraudeau S, Berezne A, Baubet T, Le-Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 2007;57:94-102.
12. Mouthon L, Rannou F, Berezne A, Pagnoux C, Arene JP, Fois E, et al. Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale. Ann Rheum Dis 2007;66:1651-5.
13. Hewlett S, Smith AP, Kirwan JR. Values for function in rheumatoid arthritis: patients, professionals, and public. Ann Rheum Dis 2001;60:928-33.
14. Tugwell P, Bombardier C, Buchanan WW, Goldsmith C, Grace E, Bennett KJ, et al. Methotrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med 1990;150:59-62.
15. Tugwell P, Bombardier C, Buchanan WW, Goldsmith CH, Grace E, Hanna B. The MACTAR Patient Preference Disability Questionnaire: an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol 1987;14:446-51.
16. Verhoeven AC, Boers M, van der Liden S. Validity of the MACTAR questionnaire as a functional index in a rheumatoid arthritis clinical trial. J Rheumatol 2000;27:2801-9.
17. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
18. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
19. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al, for the Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
20. Georges C, Chassany O, Mouthon L, Tiev K, Toledano C, Meyer O, et al. Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol 2005;24:3-10.
21. Duruoz MT, Poiraudeau S, Fermanian J, Menkes CJ, Amor B, Dougados M, et al. Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap. J Rheumatol 1996;23:1167-72.
22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
23. Fermanian J. Measuring agreement between 2 observers: a quantitative case. Rev Epidemiol Sante Publique 1984;32:408-13. In French.
24. Evans C, McCarthy M. Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet 1985;1:1204-6.
25. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665-72.
26. Imaizumi T, Chiba M, Honma T, Niwa J. Detection of hemosiderin deposition by T2*-weighted MRI after subarachnoid hemorrhage. Stroke 2003;34:1693-8.
27. Molina JM, Tourneur M, Sarfati C, Chevret S, de Gouvello A, Gobert JG, et al, and the Agence Nationale de Recherches sur le SIDA 090 Study Group. Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 2002;346:1963-9.
28. Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R, et al. Development of a prognostic model for grading chronic graft-versus-host disease [published erratum appears in Blood 2002;99:14]. Blood 2001;97:1219-26.
29. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet 2001;357:841-7.